Revenue surged 36.7% but profitability guidance fell as medical costs climbed.
ALHC Alignment Healthcare, Inc. Common Stock
XNAS
7.01
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ALHC
$7.01
—
Key stats
$7.01
- 52-Week Range
- $6.01 – $25.12
- YTD
- -65.31%
- IV Rank (30D)
- 36.82
- Straddle Price
- $0.97
- P/C Vol Ratio
- 0.02
- Market Cap
- $1.5B
- Open
- $7.39
- Day Range
- $6.92 – $7.41
- Volume
- 4,688,597
- Prev Close
- $7.27
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.05% |
| Beta vs SPY | 0.88 |
| Cost of Equity (CAPM) | 9.46% (VRP-adj) |
| WACC | 8.77% |
| Volatility Risk Premium | +174.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 10.4% |
| Book / Price | 18.7% |
| Gross Margin (TTM) | 10.8% |
| FCF Margin (TTM) | 1.6% |
| Debt / Equity | 1.17 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | -1.0% (reverse-DCF on current price) |
| SMA 50 | $9.87 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $8.20 |
| Bollinger Width / SMA20 | 198.7% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $1B |
Peers used for multiples: DXCM, GEHC, IRTC, ISRG, MRNA, PHG, PODD, RMD
Blended Fair Value
$21.49
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $20.33 | 13% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $3.72 | 8% | median 28.2× · 5 peers |
| Peer EV/EBITDA | $3.06 | 8% | median 19.1× · 6 peers |
| Peer P/B | $13.46 | 8% | median 9.9× · 7 peers |
| Peer P/S | $155.30 | 8% | median 5.9× · 7 peers |
| Market Anchor (SMA50) | $9.87 | 42% | stability 81% (BB-width) |
| Options Expected (B-L 30d) | $7.77 | 14% | 11 strikes · skew +0.13 |
As of 2026-11-02 · updated
Related
About
- Industry (SIC)
- HOSPITAL & MEDICAL SERVICE PLANS (6324) · industry map
- Exchange
- XNAS
- Market Cap
- $1.5B
- Employees
- 1,849
- List Date
- 2021-03-26
- CIK
- 0001832466
- Headquarters
- Orange, CA
- Homepage
- https://www.alignmenthealth.com
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -45.52% | 6.37% | -21.08% | 33.13% | 11.42% | -3.14% |
| Feb | -- | 9.61% | -20.35% | -7.41% | 2.08% | -15.14% | -6.24% |
| Mar | 26.69% | 33.06% | -20.80% | -12.06% | 19.97% | -10.33% | 6.09% |
| Apr | 14.40% | -18.00% | -7.09% | 4.46% | -1.99% | 26.27% | 3.01% |
| May | -4.21% | 6.59% | -14.31% | 50.96% | -8.35% | -24.38% | 1.05% |
| Jun | -6.52% | 11.53% | -2.54% | -2.13% | -9.74% | 79.02% | 11.60% |
| Jul | -8.60% | 26.44% | 7.25% | 9.66% | -3.03% | -37.96% | -1.04% |
| Aug | -15.25% | 3.26% | -0.68% | 4.52% | 26.14% | -7.97% | 1.67% |
| Sep | -12.10% | -20.00% | 20.70% | 20.49% | 4.87% | -39.96% | -4.33% |
| Oct | 18.07% | 8.52% | -2.13% | 24.00% | 0.24% | -6.07% | 7.11% |
| Nov | -18.75% | -2.78% | 12.61% | -2.63% | 14.07% | 0.00%* | 0.42% |
| Dec | -7.26% | -9.61% | 16.98% | -12.38% | 3.51% | -- | -1.75% |
| Total | -21.38% | -22.85% | -13.70% | 44.89% | 100.69% | -53.33% | 5.72% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $8.13
SMA 50: $9.75
SMA 200: $16.73
Current: $7.04
EMA 12: $7.90
EMA 26: $8.44
MACD: -0.5473 | Signal: 0.0325
BEARISH
ADX (14): 37.15
TREND
+DI: 14.42
−DI: 37.22
Momentum Oscillators
RSI (14): 29.81
OVERSOLD
Stoch %K: 21.16
Stoch %D: 45.29
Williams %R: -92.77
Volume & Volatility
BB Upper: $8.95
BB Lower: $7.31
OVERSOLD
OBV: -222,499,339
Vol SMA 20: 7,899,598
Vol ROC: 28.24%
ATR: $0.55
True Range: $0.49
HV 20: 74.0%
HV 30: 72.0%
HV 60: 79.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-01T00:00:00 – 2026-10-30T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with a confidence level of 6/10.
Key drivers: Recent negative news headlines, technical indicators suggesting a trend reversal.
Primary risks: High volatility, potential for further price declines if regulatory issues persist.
Investment thesis: ALHC is likely to experience a short-term correction due to the recent surge in negative news sentiment. A potential rebound may occur if the company addresses the concerns raised by investors and regulators.
Recent news sentiment impact: The overwhelming negative tone of recent headlines has contributed to the current decline, but it's essential to monitor any changes in market perception.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bearish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: $13.46 (SMA 20), $14.03 (Upper Bollinger Band), and $18.88 (SMA 200)
Momentum Signals:
- RSI interpretation: Neutral (38.87)
- MACD signal: Bearish (-0.82 / Signal: 0.27 / Histogram: -1.09)
- Bollinger Bands position: Neutral
Volume Analysis:
- Volume trends: Increasing volume with a rate of change indicating growing interest
- Institutional interest signals: Mixed, with some institutions buying and others selling
News & Sentiment Analysis
Recent Headlines Summary: Recent news headlines have been overwhelmingly negative, focusing on regulatory issues, whistleblower allegations, and potential financial manipulation.
Sentiment Assessment: Aggregate sentiment is strongly negative (6/10).
Catalyst Identification: The company's response to the recent allegations and regulatory concerns will be crucial in determining its future direction.
Market Narrative: The current market narrative emphasizes caution and skepticism regarding ALHC's prospects.
Risk & Volatility Assessment
Risk Assessment:
- Beta interpretation: Low risk (0.31 vs SPY)
- Volatility regime: Historical volatility is relatively low
- Options market signals: IV rank is 16.2% (low), indicating historically low volatility, but the put/call ratio suggests bearish sentiment
Downside Protection: Support levels include $13.46 (SMA 20) and $12.90 (Lower Bollinger Band).
Market Context & Positioning
Sector Performance: ALHC is performing poorly compared to its sector peers.
Institutional Activity: Mixed institutional interest signals, with some institutions buying and others selling.
Correlation Analysis: The stock has a low correlation with the market (R-squared interpretation), indicating it may be more susceptible to volatility and news-driven price movements.
Relative Valuation: ALHC is relatively undervalued compared to its peers, potentially creating a long-term opportunity.
Key Levels & Action Items
Critical Price Levels:
- Support/resistance at $13.46 (SMA 20) and $14.03 (Upper Bollinger Band)
- Breakout/breakdown levels: $12.90 (Lower Bollinger Band) and $18.88 (SMA 200)
Time-Sensitive Catalysts:
- Company's response to recent allegations and regulatory concerns
- Earnings data availability
Risk Management:
- Stop-loss levels: Consider setting a stop-loss at $12.90 or $13.46 based on market conditions and risk tolerance
- Position sizing considerations: Reduce exposure if the stock price falls below $13.46 or increase exposure if it rises above $14.03
Please note that this analysis is based on the provided data and may not account for all possible factors affecting the stock's performance. It is essential to continuously monitor market conditions, news sentiment, and technical indicators to adjust your analysis and make informed investment decisions.
Generated
News
All ALHC news →
Alignment Healthcare swung to an $8 million loss as the industrywide struggle grappling with costs of care for older adults in Medicare Advantage plans lingers.
Showing 1–10 of 13
Page 1 of 2
Earnings History
15 of 21 under expected move
Avg Expected Move
14.72%
Avg Actual Move
9.37%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-17 | After-Close | 12.53% | 0.84% | 0.07x | Within |
| 2021-08-09 | After-Close | 6.04% | 8.41% | 1.39x | Exceeded |
| 2021-11-04 | After-Close | 5.02% | 5.74% | 1.14x | Exceeded |
| 2022-03-03 | After-Close | 18.67% | 11.93% | 0.64x | Within |
| 2022-08-04 | After-Close | 5.66% | 6.73% | 1.19x | Exceeded |
| 2023-02-28 | After-Close | 8.05% | 19.22% | 2.39x | Exceeded |
| 2023-05-04 | After-Close | 13.71% | 1.57% | 0.11x | Within |
| 2023-08-03 | After-Close | 14.71% | 11.59% | 0.79x | Within |
| 2023-11-02 | After-Close | 14.96% | 5.20% | 0.35x | Within |
| 2024-02-27 | After-Close | 21.68% | 18.21% | 0.84x | Within |
| 2024-05-02 | After-Close | 12.93% | 26.05% | 2.01x | Exceeded |
| 2024-08-01 | After-Close | 23.20% | 3.71% | 0.16x | Within |
| 2024-10-29 | After-Close | 22.84% | 0.17% | 0.01x | Within |
| 2025-02-27 | After-Close | 17.26% | 16.48% | 0.95x | Within |
| 2025-05-01 | After-Close | 15.95% | 7.39% | 0.46x | Within |
| 2025-07-30 | After-Close | 22.69% | 6.00% | 0.26x | Within |
| 2025-10-30 | After-Close | 12.70% | 1.52% | 0.12x | Within |
| 2026-02-26 | After-Close | 12.24% | 5.88% | 0.48x | Within |
| 2026-04-30 | After-Close | 13.75% | 10.12% | 0.74x | Within |
| 2026-07-30 | After-Close | 15.58% | 20.20% | 1.30x | Exceeded |
| 2026-10-29 | After-Close | 18.92% | 9.80% | 0.52x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ALHC Options Activity & IV Rank
ALHC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 74.0%
7-DTE IV: 75.7%
Expected Move: $0.97
7-DTE Move: $0.97
Days to Exp: 18 (2026-11-20)
Options Flow
Call Volume: 6,907
Put Volume: 155
P/C Volume: 0.022
BULLISH
Call OI: 36,007
Put OI: 1,688
P/C OI: 0.047
Total OI: 37,695
ATM Options Pricing
ATM Call: $0.25
ATM Put: $0.72
Call %: 3.6%
Put %: 10.3%
Chain Summary
Chain Volume: 11,303
Chain OI: 69,715
Last Updated: 11/2/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 13th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
13%
vs own history
GEX tilt
-0.47
OI-weighted, today
Vanna tilt
-0.48
δ-sensitivity to IV
Charm tilt
+0.34
δ-decay vs time
Vanna tilt -0.48: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.34: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM 69.4% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)13.9LowNov 2
IV Rank (30 DTE)36.8MediumNov 2
Straddle Price (30 DTE)$0.97Nov 2
Beta Analysis
Risk Metrics
Beta: 0.4449
Alpha: -67.57%
Correlation: 0.0813
R-Squared: 0.7%
Stock Volatility: 70.0%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ALHC
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $34.8M | #804 of 3716 | -61.9% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $23.8M | #628 of 3138 | -65.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $83K | #3087 of 4729 | +9.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ALHC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 204,170,118 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
11 filers$75.41M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $32.00M | 42.43% | 2026-06-30 |
| 2 | Caption Management, LLC | $14.29M | 18.95% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $13.02M | 17.27% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $7.38M | 9.78% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $1.95M | 2.59% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $1.83M | 2.42% | 2026-06-30 |
| 7 | HBK INVESTMENTS L P | $1.66M | 2.20% | 2026-06-30 |
| 8 | Walleye Trading LLC | $1.32M | 1.75% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $1.14M | 1.51% | 2026-06-30 |
| 10 | TUDOR INVESTMENT CORP ET AL | $457.15K | 0.61% | 2026-06-30 |
| 11 | HAP TRADING, LLC | $369.08K | 0.49% | 2025-09-30 |
8 filers$13.58M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $8.18M | 60.22% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $3.40M | 25.08% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $1.22M | 8.98% | 2026-06-30 |
| 4 | Walleye Capital LLC | $342.86K | 2.53% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $273.81K | 2.02% | 2026-06-30 |
| 6 | Walleye Trading LLC | $128.57K | 0.95% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $26.19K | 0.19% | 2026-06-30 |
| 8 | WOLVERINE ASSET MANAGEMENT LLC | $4.76K | 0.04% | 2026-06-30 |
ALHC Insider Trading (Form 4)
Latest: 2026-10-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Hyong Kim | Chief Medical Officer | Sell (S) | −32,479 | $8.30 | -$269.6K | EDGAR |
| 2026-09-18 | Joseph S Konowiecki | EVP, Corporate Affairs | Sell (S) | −23,511 | $8.61 | -$202.4K | EDGAR |
| 2026-09-16 | John E Kao | Chief Executive Officer | Sell (S) | −27,400 | $13.00 | -$356.2K | EDGAR |
| 2026-09-11 | Dawn Christine Maroney | President | Sell (S) | −122,707 | $12.68 | -$1.56M | EDGAR |
| 2026-09-11 | John E Kao | Chief Executive Officer | Sell (S) | −557,870 | $12.77 | -$7.12M | EDGAR |
| 2026-08-18 | Dawn Christine Maroney | President | Sell (S) | −5,000 | $14.00 | -$70.0K | EDGAR |
| 2026-08-10 | John E Kao | Chief Executive Officer | Sell (S) | −298,000 | $13.88 | -$4.14M | EDGAR |
| 2026-07-16 | Dawn Christine Maroney | President | Mixed | −25,000 | $15.39 | -$2.31M | EDGAR |
| 2026-07-14 | John E Kao | Chief Executive Officer | Sell (S) | −298,000 | $19.86 | -$5.92M | EDGAR |
| 2026-07-02 | Shane J. Hochradel | Chief Operations Officer | Award (A) | +87,719 | — | EDGAR | |
| 2026-07-01 | Joseph S Konowiecki | EVP, Corporate Affairs | Sell (S) | −25,000 | $24.00 | -$600.0K | EDGAR |
| 2026-06-26 | Joseph S Konowiecki | EVP, Corporate Affairs | Sell (S) | −25,000 | $23.00 | -$575.0K | EDGAR |
| 2026-06-18 | Joseph S Konowiecki | EVP, Corporate Affairs | Sell (S) | −25,000 | $22.00 | -$550.0K | EDGAR |
| 2026-06-15 | Dawn Christine Maroney | President | Sell (S) | −30,000 | $19.55 | -$586.4K | EDGAR |
| 2026-06-15 | Hyong Kim | Chief Medical Officer | Sell (S) | −35,951 | $19.86 | -$713.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ALHC Insider Holdings
26 insiders · @ $7.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | GAP COINVESTMENTS IV, LLC | Director | 61,302,175 | $431.87M | -$1.26B | 2 | 2025-03-17 |
| 2 | General Atlantic (SPV) GP, LLC | Director | 30,842,175 | $217.28M | -$4.75B | 2 | 2025-09-16 |
| 3 | General Atlantic Partners 95, L.P. | Director | 24,596,079 | $173.28M | -$1000.00M | 1 | 2025-09-19 |
| 4 | General Atlantic (ALN HLTH), L.P. | Director | 13,476,585 | $94.94M | -$1.25B | 11 | 2025-12-12 |
| 5 | GAP Coinvestments CDA, L.P. | Director | 13,476,585 | $94.94M | -$2.06B | 2 | 2025-12-12 |
| 6 | John E Kao | Chief Executive Officer | 1,814,239 | $12.78M | -$142.08M | 59 | 2026-09-16 |
| 7 | Robert Thomas Freeman | Chief Financial Officer | 1,557,348 | $10.97M | -$19.76M | 36 | 2025-03-28 |
| 8 | Joseph S Konowiecki | EVP, Corporate Affairs | 1,080,305 | $7.61M | -$5.25M | 27 | 2026-09-18 |
| 9 | Dawn Christine Maroney | President | 794,606 | $5.60M | -$51.17M | 65 | 2026-09-11 |
| 10 | Hakan Kardes | Chief Experience Officer | 678,987 | $4.78M | -$3.91M | 14 | 2025-03-28 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ALHC Board & Officers
As of SEC filings through Oct 7, 2026Directors 9
- David C Hodgson · since Mar 26, 2021
- Jacqueline B Kosecoff · since Mar 26, 2021
- John E Kao · since Mar 26, 2021
- Joseph S Konowiecki · since Mar 26, 2021
- Margaret M McCarthy · since Mar 26, 2021
- Mark B. McClellan · since Mar 26, 2021
- Nicholas Robbert Vorhoff · since Mar 26, 2021
- Jody L Bilney · since Jan 1, 2022
- Yon Jorden · since Jan 1, 2022
Officers 12
- John E Kao · Chief Executive Officer · since Mar 26, 2021
- Dawn Christine Maroney · President · listed since Jan 2025
- Mark D. Kent · President - MSO · since May 12, 2026
- James M Head · Chief Financial Officer · since May 2, 2025
- Sebastian Burzacchi · COO - Mgmt Services Org · since Nov 27, 2023
- Robert L. Scavo · Chief Information Officer · since Apr 20, 2023
- Christopher J Joyce · Chief Legal and Admin. Officer · since Aug 1, 2023
- Hyong Kim · Chief Medical Officer · since Sep 25, 2023
- Andreas P. Wagner · Chief Human Resources Officer · listed since Feb 2025
- Adnan R. Mansour · Chief Digital Officer · since Jan 19, 2026
- Shane J. Hochradel · Chief Operations Officer · since Jun 1, 2026
- Joseph S Konowiecki · EVP, Corporate Affairs · listed since Jun 2026
Changes in the last 10 years (114)
| Jun 9, 2026 | Joseph S Konowiecki first listed as EVP, Corporate Affairs in an SEC filing |
| Jun 1, 2026 | Shane J. Hochradel became Chief Operations Officer |
| May 12, 2026 | Mark D. Kent became President - MSO |
| Jan 19, 2026 | Adnan R. Mansour became Chief Digital Officer |
| Dec 12, 2025 | General Atlantic, L.p. reported in an SEC filing no longer being a director |
| Dec 12, 2025 | General Atlantic, L.p. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | General Atlantic Partners 95, L.P. reported in an SEC filing no longer being a director |
| Dec 12, 2025 | General Atlantic Partners 95, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | General Atlantic Genpar, L.p. reported in an SEC filing no longer being a director |
| Dec 12, 2025 | General Atlantic Genpar, L.p. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | General Atlantic (SPV) GP, LLC reported in an SEC filing no longer being a director |
| Dec 12, 2025 | General Atlantic (SPV) GP, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | General Atlantic (ALN HLTH), L.P. reported in an SEC filing no longer being a director |
| Dec 12, 2025 | General Atlantic (ALN HLTH), L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | Gapco Management Gmbh reported in an SEC filing no longer being a director |
| Dec 12, 2025 | Gapco Management Gmbh reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | Gapco Gmbh & Co Kg reported in an SEC filing no longer being a director |
| Dec 12, 2025 | Gapco Gmbh & Co Kg reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | Gap Coinvestments IV, LLC reported in an SEC filing no longer being a director |
| Dec 12, 2025 | Gap Coinvestments IV, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | Gap Coinvestments III, LLC reported in an SEC filing no longer being a director |
| Dec 12, 2025 | Gap Coinvestments III, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | GAP Coinvestments V, LLC reported in an SEC filing no longer being a director |
| Dec 12, 2025 | GAP Coinvestments V, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2025 | GAP Coinvestments CDA, L.P. reported in an SEC filing no longer being a director |
| Dec 12, 2025 | GAP Coinvestments CDA, L.P. reported in an SEC filing no longer being a 10% owner |
| May 2, 2025 | James M Head became Chief Financial Officer |
| Apr 9, 2025 | The company announced the departure of Hakan Kardes as Chief Experience Officer in an SEC filing |
| Feb 12, 2025 | Andreas P. Wagner listed as Chief Human Resources Officer (previously Chief People & Culture Officer) in SEC filings |
| Jan 17, 2025 | Dawn Christine Maroney listed as President (previously President, Markets) in SEC filings |
| Aug 16, 2024 | Jeffrey H Margolis reported in an SEC filing no longer being a director |
| Aug 13, 2024 | The company announced the departure of Thomas J. Carella from the board in an SEC filing |
| Jul 19, 2024 | Joseph S Konowiecki no longer listed as Chairman of the Board in SEC filings |
| Mar 15, 2024 | Hakan Kardes listed as Chief Experience Officer (previously Chief Technology Officer) in SEC filings |
| Jan 8, 2024 | Andreas P. Wagner became Chief People & Culture Officer |
| Nov 27, 2023 | Sebastian Burzacchi became COO - Mgmt Services Org |
| Sep 25, 2023 | Hyong Kim became Chief Medical Officer |
| Aug 9, 2023 | The company announced the departure of Dinesh M. Kumar as Chief Med & Operating Officer in an SEC filing |
| Aug 1, 2023 | Christopher J Joyce became Chief Legal and Admin. Officer |
| Jul 11, 2023 | The company announced the departure of Richard A. Cross as SVP, General Counsel in an SEC filing |
| Jun 30, 2023 | Melinda Michele Kimbro became Chief People Officer |
| Apr 20, 2023 | Robert L. Scavo became Chief Information Officer |
| Apr 20, 2023 | Hakan Kardes became Chief Technology Officer |
| Nov 9, 2022 | Joseph S Konowiecki first listed as Chairman of the Board in an SEC filing |
| Jun 17, 2022 | Dinesh M. Kumar listed as Chief Med & Operating Officer (previously Chief Medical Officer) in SEC filings |
| Apr 1, 2022 | Rajesh Shrestha reported in an SEC filing no longer being Pres., New Markets & CBO |
| Jan 1, 2022 | Yon Jorden became a director |
| Jan 1, 2022 | Jody L Bilney became a director |
| Nov 24, 2021 | Warburg Pincus Partners II Holdings, L.P. first on file as a director |
| Nov 24, 2021 | Warburg Pincus Partners II Holdings, L.P. first on file as a 10% owner |
| Oct 15, 2021 | Dinesh M. Kumar listed as Chief Medical Officer (previously Chief Health Officer) in SEC filings |
| Aug 27, 2021 | Richard A. Cross became SVP, General Counsel |
| Aug 27, 2021 | Rajesh Shrestha became Pres., New Markets & CBO |
| Mar 26, 2021 | Warburg Pincus Xii, L.p. became a director |
| Mar 26, 2021 | Warburg Pincus Xii, L.p. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus XII Partners, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus XII Partners, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-E, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-E, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-D, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-D, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-B, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus Private Equity XII-B, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Private Equity XII, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus Private Equity XII, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Partners II, L.P. became a director |
| Mar 26, 2021 | Warburg Pincus Partners II, L.P. became a 10% owner |
| Mar 26, 2021 | Warburg Pincus Partners GP LLC became a director |
| Mar 26, 2021 | Warburg Pincus Partners GP LLC became a 10% owner |
| Mar 26, 2021 | Warburg Pincus LLC became a director |
| Mar 26, 2021 | Warburg Pincus LLC became a 10% owner |
| Mar 26, 2021 | WP XII Partners, L.P. became a director |
| Mar 26, 2021 | WP XII Partners, L.P. became a 10% owner |
| Mar 26, 2021 | WP Global LLC became a director |
| Mar 26, 2021 | WP Global LLC became a 10% owner |
| Mar 26, 2021 | WARBURG PINCUS & CO. became a director |
| Mar 26, 2021 | WARBURG PINCUS & CO. became a 10% owner |
| Mar 26, 2021 | Thomas J. Carella became a director |
| Mar 26, 2021 | Robert Thomas Freeman became Chief Financial Officer |
| Mar 26, 2021 | Nicholas Robbert Vorhoff became a director |
| Mar 26, 2021 | Michael Curtis Foster became Chief Legal Officer |
| Mar 26, 2021 | Mark B. McClellan became a director |
| Mar 26, 2021 | Margaret M McCarthy became a director |
| Mar 26, 2021 | Joseph S Konowiecki became a director |
| Mar 26, 2021 | John E Kao became a director |
| Mar 26, 2021 | John E Kao became Chief Executive Officer |
| Mar 26, 2021 | Jeffrey H Margolis became a director |
| Mar 26, 2021 | Jacqueline B Kosecoff became a director |
| Mar 26, 2021 | General Atlantic, L.p. became a director |
| Mar 26, 2021 | General Atlantic, L.p. became a 10% owner |
| Mar 26, 2021 | General Atlantic Partners 95, L.P. became a director |
| Mar 26, 2021 | General Atlantic Partners 95, L.P. became a 10% owner |
| Mar 26, 2021 | General Atlantic Genpar, L.p. became a director |
| Mar 26, 2021 | General Atlantic Genpar, L.p. became a 10% owner |
| Mar 26, 2021 | General Atlantic (SPV) GP, LLC became a director |
| Mar 26, 2021 | General Atlantic (SPV) GP, LLC became a 10% owner |
| Mar 26, 2021 | General Atlantic (ALN HLTH), L.P. became a director |
| Mar 26, 2021 | General Atlantic (ALN HLTH), L.P. became a 10% owner |
| Mar 26, 2021 | Gapco Management Gmbh became a director |
| Mar 26, 2021 | Gapco Management Gmbh became a 10% owner |
| Mar 26, 2021 | Gapco Gmbh & Co Kg became a director |
| Mar 26, 2021 | Gapco Gmbh & Co Kg became a 10% owner |
| Mar 26, 2021 | Gap Coinvestments IV, LLC became a director |
| Mar 26, 2021 | Gap Coinvestments IV, LLC became a 10% owner |
| Mar 26, 2021 | Gap Coinvestments III, LLC became a director |
| Mar 26, 2021 | Gap Coinvestments III, LLC became a 10% owner |
| Mar 26, 2021 | GAP Coinvestments V, LLC became a director |
| Mar 26, 2021 | GAP Coinvestments V, LLC became a 10% owner |
| Mar 26, 2021 | GAP Coinvestments CDA, L.P. became a director |
| Mar 26, 2021 | GAP Coinvestments CDA, L.P. became a 10% owner |
| Mar 26, 2021 | Donald Steven Furman became Chief Clinical Officer |
| Mar 26, 2021 | Dinesh M. Kumar became Chief Health Officer |
| Mar 26, 2021 | Dawn Christine Maroney became President, Markets |
| Mar 26, 2021 | David C Hodgson became a director |
Not reported recently (17)
- Robert Thomas Freeman · Last reported as Chief Financial Officer in an SEC filing dated Mar 28, 2025
- Donald Steven Furman · Last reported as Chief Clinical Officer in an SEC filing dated Aug 22, 2023
- Melinda Michele Kimbro · Last reported as Chief People Officer in an SEC filing dated Jul 7, 2023
- Warburg Pincus LLC · Last reported as a director in an SEC filing dated Sep 20, 2022
- WARBURG PINCUS & CO. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Partners GP LLC · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Xii, L.p. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Partners II, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- WP Global LLC · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus XII Partners, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Private Equity XII-D, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Private Equity XII-B, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- WP XII Partners, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Private Equity XII, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Private Equity XII-E, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Warburg Pincus Partners II Holdings, L.P. · Last reported as a director in an SEC filing dated Sep 20, 2022
- Michael Curtis Foster · Last reported as Chief Legal Officer in an SEC filing dated Apr 8, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ALHC Proposed Insider Sales (Form 144)
Latest: 2026-10-05
? Form 144 Guide
Last 30d:
1 filing
· $305K notice value
· Last 90d:
6 filings
· $14.1M notice value
· 4 unique filers
· 33% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
John Kao (2, $11.8M) · DAWN MARONEY (2, $1.8M) · Hyong (Ken) Kim, M.D. (1, $305K) · Joseph Konowiecki (1, $226K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | Hyong (Ken) Kim, M.D. | Chief Medical Officer | 36,000 | $305.3K | 2026-10-06 | E-Trade Finance | — | EDGAR |
| 2026-09-16 | Joseph Konowiecki | Director / EVP, Corporate Affairs | 26,000 | $226.5K | 2026-09-17 | E-Trade Finance | — | EDGAR |
| 2026-09-10 | JEK TRUST U/A DTD 02/08/2021 | Director, Officer | 500,000 | $6.51M | 2026-09-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-09 | Dawn C. Maroney | President | 130,000 | $1.70M | 2026-09-10 | E-Trade Finance | — | EDGAR |
| 2026-09-09 | John Kao | Chief Executive Officer / Director | 405,000 | $5.29M | 2026-09-10 | E-Trade Finance | — | EDGAR |
| 2026-08-14 | DAWN MARONEY | Officer | 5,000 | $67.3K | 2026-08-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-15 | DAWN MARONEY | Officer | 177,068 | $3.75M | 2026-07-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-10 | JEK TRUST U/A DTD 02/08/2021 | Director, Officer | 596,000 | $12.53M | 2026-07-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-01 | Joseph Konowiecki | Director | 25,000 | $600.0K | 2026-07-01 | Merrill Lynch | — | EDGAR |
| 2026-06-26 | Joseph Konowiecki | Director | 25,000 | $575.0K | 2026-06-26 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
102 ETFs hold ALHC
25 shown · $367.22M total exposure · 0.08% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.08% | $81.6M | $105.6B | 2026-10-30 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $48.4M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.05% | $37.3M | $75.5B | 2026-10-30 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $34.3M | — | 2026-09-30 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.04% | $19.1M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $17.2M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.10% | $13.9M | $14.0B | 2026-10-30 |
| 8 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.08% | $13.7M | $16.2B | 2026-10-29 |
| 9 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.16% | $12.3M | $7.5B | 2026-10-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $11.8M | — | 2026-05-31 |
| 11 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $10.8M | — | 2026-10-29 |
| 12 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.05% | $9.7M | — | 2026-09-30 |
| 13 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.18% | $8.5M | $4.8B | 2026-10-29 |
| 14 | CPAI Counterpoint Quantitative Equity ETF | Nport | 2.01% | $7.4M | — | 2026-06-30 |
| 15 | PSC Principal U.S. Small-Cap ETF | Nport | 0.27% | $6.2M | — | 2026-06-30 |
| 16 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.09% | $5.4M | — | 2026-09-30 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.9M | — | 2026-09-30 |
| 18 | JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | JPMorgan | 0.16% | $4.7M | $2.9B | 2026-10-30 |
| 19 | RWJ Invesco S&P SmallCap 600 Revenue ETF | Invesco | 0.18% | $3.6M | — | 2026-10-29 |
| 20 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $3.4M | — | 2026-10-29 |
| 21 | SEIS SEI Select Small Cap ETF | Nport | 0.56% | $3.2M | — | 2026-06-30 |
| 22 | ASCE Allspring SMID Core ETF | Nport | 2.15% | $2.5M | — | 2026-06-30 |
| 23 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.08% | $2.5M | $3.2B | 2026-10-29 |
| 24 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 0.17% | $2.5M | $1.5B | 2026-10-30 |
| 25 | XHS State Street® SPDR® S&P® Health Care Services ETF | SPDR (State Street) | 1.02% | $2.4M | $233.7M | 2026-10-29 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
58.46
TTM Diluted EPS
$0.12
TTM Revenue
$4.88B
TTM Net Income
$28.92M
TTM Op. Cash Flow
$108.02M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $1.35B | $-8.05M | $-0.04 | $47.03M |
| Q2 '26 | 2026-06-30 | $1.33B | $36.56M | $0.17 | $-17.31M |
| Q1 '26 | 2026-03-31 | $1.23B | $11.42M | $0.05 | $128.68M |
| Q4 '25 | 2025-12-31 | $975.80M | $-11.01M | — | $-50.38M |
| Q3 '25 | 2025-09-30 | $983.68M | $3.73M | $0.02 | $144.56M |
| Q2 '25 | 2025-06-30 | $1.01B | $15.67M | $0.07 | $29.13M |
| Q1 '25 | 2025-03-31 | $918.04M | $-9.11M | $-0.05 | $16.62M |
| Q4 '24 | 2024-12-31 | $669.61M | $-31.09M | $-0.16 | $-8.71M |
| Q3 '24 | 2024-09-30 | $692.43M | $-26.41M | $-0.14 | $26.19M |
| Q2 '24 | 2024-06-30 | $681.29M | $-24.01M | $-0.13 | $23.53M |
| Q1 '24 | 2024-03-31 | $628.60M | $-46.52M | $-0.25 | $-6.24M |
| Q4 '23 | 2023-12-31 | $459.01M | $-47.21M | $-0.25 | $-187.47M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
29.23
P/B
5.52
P/S
0.32
EV/EBITDA
34.26
EV/Sales
0.24
ROE
15.4%
ROA
3.2%
Div Yield
0.00%
FCF Yield
14.04%
Debt/Equity
1.22
Current Ratio
—
Market Cap
$1.46B
as of 2026-11-02
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
25.52M
SI % of Float
13.97%
Days to Cover
2.25
Short Vol Ratio
34.5%
Free Float
182.71M
Float %
88.1%
Short interest 2026-10-15 • Short volume 2026-10-30 • Float 2026-08-14